Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign
- PMID: 39137766
- PMCID: PMC11448546
- DOI: 10.4269/ajtmh.24-0181
Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign
Abstract
Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05-0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0-95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.
Conflict of interest statement
Disclosure: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position, policies, or views of the U.S. Centers for Disease Control and Prevention or the World Health Organization.
Figures
References
-
- World Health Organization , 2019. Typhoid vaccines: WHO position paper, March 2018—Recommendations. Vaccine 37: 214–216. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
